Super DC Vaccine by Shanghai Cell Therapy Group for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
OCTOBER 3, 2023
Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor.
Merck and Moderna partner to develop and sell cancer vaccine
Pharmaceutical Technology
OCTOBER 14, 2022
German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.
Vaccination 
289
289 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pneumococcal (23-valent) vaccine by Jiangsu Ab&b Bio-tech for Streptococcal Pneumonia: Likelihood of Approval
Pharmaceutical Technology
JANUARY 22, 2024
Pneumococcal (23-valent) vaccine is under clinical development by Jiangsu Ab&b Bio-tech and currently in Phase I for Streptococcal Pneumonia.
Vaccination 100
100 
Pneumococcal (23-valent) vaccine by Jiangsu Ab&b Bio-tech for Streptococcal Pneumonia: Likelihood of Approval
Pharmaceutical Technology
JANUARY 22, 2024
Pneumococcal (23-valent) vaccine is under clinical development by Jiangsu Ab&b Bio-tech and currently in Phase I for Streptococcal Pneumonia.
Vaccination 100
100 
Vaccine successfully lowers cholesterol in preclinical studies
Drug Discovery World
FEBRUARY 27, 2024
New studies have demonstrated that Vaxxinity’s vaccine VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease.
Vaccination 104
104 
Super DC Vaccine by Shanghai Cell Therapy Group for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
OCTOBER 3, 2023
Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor.
Vaccination 100
100 
AstriVax awarded €3m to develop therapeutic vaccine for hepatitis B
Pharma Times
DECEMBER 15, 2023
The funding builds on AstriVax’s €30m in seed funding for its vaccine platform AstriVax has announced that it has been awarded a total of €3m in funding from Flanders Innovation & Entrepreneurship (VLAIO) for its therapeutic vaccine targeting chronic hepatitis B. in May to advance the company’s innovative vaccine platform.
Vaccination 97
97 
Indonesia grants EUA for US-developed Covid-19 vaccine
Pharmaceutical Technology
OCTOBER 3, 2022
Indonesia has granted Emergency Use Authorization (EUA) for the patent-free Covid-19 vaccine, IndoVac, developed by the Texas Children’s Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine, US. PT Bio Farma will manufacture 20 million doses of the vaccine this year.
Vaccination 130
130 
Evaxion and ExpreS²ion partner to develop new CMV vaccine
Pharmaceutical Technology
DECEMBER 6, 2022
Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Based on the CMV vaccine’s clinical development stage at the time of sublicensing, Evaxion could also receive royalty payments from ExpreS 2 ion.
Vaccination 130
130 
US FDA grants approval for Merck’s pneumococcal vaccine for children
Pharmaceutical Technology
JUNE 23, 2022
The US Food and Drug Administration (FDA) has granted approval for Merck's (MSD outside the US and Canada) pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for use in children aged six weeks to 17 years. The post US FDA grants approval for Merck’s pneumococcal vaccine for children appeared first on Pharmaceutical Technology.
Vaccination 147
147 
Vaxxas raises $23m for needle-free vaccine clinical development and manufacturing
BioPharma Reporter
DECEMBER 5, 2022
Vaxxas has completed a financing round which raised US$23m (A$34m) in new funds: allowing the company to progress multiple vaccine programs in the clinic and ramp up manufacturing capabilities towards commercial scale.
Influenza vaccine 2 by Shanghai Institute of Biological Products for Pandemic Influenza: Likelihood of Approval
Pharmaceutical Technology
JUNE 10, 2023
Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Influenza vaccine 2 LoA Report. Buy the report here.
Production 100
100 
Influenza vaccine 2 by Shanghai Institute of Biological Products for Pandemic Influenza: Likelihood of Approval
Pharmaceutical Technology
JUNE 10, 2023
Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Influenza vaccine 2 LoA Report. Buy the report here.
Production 100
100 
MinervaX reveals financing to development group B streptococcus vaccine
Pharma Times
DECEMBER 15, 2022
Plans include phase 3 clinical development of novel GBS vaccine and an efficacy evaluation
Vaccination 106
106 
Merck and Orna partner for RNA technology-based vaccines and therapies
Pharmaceutical Technology
AUGUST 17, 2022
Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. These programmes will include therapies and vaccines in infectious disease and oncology areas.
RNA 147
147 
Valneva and Pfizer start new Phase 2 study for Lyme disease vaccine candidate
BioPharma Reporter
MARCH 8, 2021
Valneva and Pfizer have initiated a Phase 2 study for their Lyme disease vaccine candidate: which is the only active Lyme disease vaccine in clinical development today.
Vaccination 138
138 
Botanical Solutions Inc: Transforming vaccine adjuvant production with tree bark
BioPharma Reporter
APRIL 17, 2024
BSI, sat down with Liza Laws, the senior editor of OSP and BPR to discuss his companyâs pioneering work in revolutionizing vaccine adjuvant production. During DCAT this year, Gaston Saperi from Botanical Solutions Inc.,
Production 95
95 
Pneumococcal Vaccination for Adults: Conversation with Vaccine Scientists Dr. Heather Platt and Dr. Ulrike Buchwald from Merck – Xtalks Life Science Podcast Ep. 140
XTalks
DECEMBER 13, 2023
This episode features an interview with vaccine scientists and executives from Vaccines Global Clinical Development at Merck, Dr. Heather Platt, MD, Distinguished Scientist and Pneumococcal Vaccine Lead; and Dr. Ulrike Buchwald, MD, Scientific Associate Vice President, Global Clinical Research and Pneumococcal Vaccine Section Head.
Life Science 52
52 
Novavax Announces COVID-19 Vaccine Clinical Development Progress
The Pharma Data
NOVEMBER 30, 2020
Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Novavax completed enrollment of 15,000 participants in a pivotal Phase 3 clinical trial being conducted in the U.K. GAITHERSBURG, Md.,
UK Vaccine Taskforce head lifts lid on Novavax deal
pharmaphorum
APRIL 19, 2021
The UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its COVID-19 jab there, according to the head of the country’s Vaccines Taskforce. . If you look at the development, we signed 15,000 people in six weeks in a trial set up by the NHS.
Vaccination 141
141 Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate
BioTech 365
DECEMBER 3, 2020
Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate Interim durability data from NIH-led Phase 1 study of mRNA-1273 published as … Continue reading →
€25 million to support clinical developments against Long Covid
Drug Discovery World
MARCH 8, 2023
The first €7 million of this funding contributes to the development of the Phase II clinical study in Long Covid, the first results of which should be available by the end of this year.” The post €25 million to support clinical developments against Long Covid appeared first on Drug Discovery World (DDW).
Overcoming the challenges of developing vaccines in an accelerated timeframe
pharmaphorum
NOVEMBER 20, 2022
One standout success we have all benefitted from is vaccine development, with notable vaccines from Pfizer/BioNTech, AstraZeneca, and Moderna. New hurdles from COVID-19 vaccine development. Trials testing SARS-CoV-2 vaccines saw high enrollment, which reduced the time between each clinical trial phase.
Vaccination 97
97 
GSK Canada’s New RSV Vaccine Ad Features Wayne Gretzky, Young and Old
XTalks
OCTOBER 31, 2023
GlaxoSmithKline (GSK) Canada has roped in both older and younger versions of Wayne Gretzky for a new ad for its respiratory syncytial virus (RSV) vaccine Arexvy. The RSV vaccine ad has the now 62-year-old hockey legend looking into a mirror and seeing his younger self, specifically an AI-generated 20-year-old version of himself.
Vaccination 97
97 
HilleVax Rakes in $135 Million to Rapidly Progress Norovirus Vaccine
BioSpace
SEPTEMBER 8, 2021
?The funds will be used to support further clinical development of VLP based vaccine candidate, HIL-214, to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection.
Vaccination 103
103 
Merck and Moderna to develop a personalised cancer vaccine
Drug Discovery World
OCTOBER 14, 2022
Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The post Merck and Moderna to develop a personalised cancer vaccine appeared first on Drug Discovery World (DDW).
Vaccination 97
97 
DDW Cancer Research Summit: Insight on therapeutic cancer vaccines
Drug Discovery World
OCTOBER 24, 2023
One of the key presentations will be given by Dr Qasim Ahmad, Chief Medical Officer of IO Biotech, a Clinical Oncologist with two decades of strategic clinical development, medical affairs, and marketing authorisation expertise. Register for free to secure your place!
Vaccination 52
52 
Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer
The Pharma Data
MARCH 23, 2022
Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. He also led the expansion of Merck’s research and development in China and Japan. “It Baynes will be succeeded by Dr. Eliav Barr, senior vice president, Global Clinical Development.
Trials of Valneva COVID-19 vaccine begin in UK
pharmaphorum
DECEMBER 17, 2020
Trials of a fifth COVID-19 vaccine have begun in the UK, as IT issues threaten to delay the roll-out of the shot from Pfizer/BioNTech. France’s Valneva begun the phase 1/2 clinical study of the inactivated vaccine candidate VLA2001 in sites across the UK, supported by the National Institute for Health Research (NIHR).
Vaccination 105
105 
Industry review: Regulatory harmonization would enable robust and timely clinical development of vaccines
BioPharma Reporter
MARCH 3, 2021
Convergence towards common global standards for clinical trial application (CTA) rules, along with unilateral and mutual recognition of CTA approvals are some suggestions made by industry insiders in a new paper to enable robust and timely development of vaccines.
Ex-GSK vaccine chief to lead new UK biotech Vicebio
pharmaphorum
JULY 21, 2022
GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called Vicebio that will go up against his former employer with a vaccine against respiratory syncytial virus (RSV) infections. ” The post Ex-GSK vaccine chief to lead new UK biotech Vicebio appeared first on. . ” He said.
Vaccination 104
104 
Sanofi and GSK begin clinical trials of coronavirus vaccine
pharmaphorum
SEPTEMBER 4, 2020
Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. The French pharma in April joined forces with the UK’s GSK to produce the vaccine, with Sanofi contributing an antigen that produces the immune reaction.
Clinical Trials 100
100 
Chinese regulator approves personalised cancer vaccine trial
Drug Discovery World
MARCH 30, 2023
Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.
Regulation 52
52 
Valneva accelerates Lyme disease vaccine R&D project with Pfizer
pharmaphorum
DECEMBER 4, 2020
Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.
Vaccination 119
119 
Digital innovation drives vaccine development
pharmaphorum
JANUARY 31, 2022
It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Innovative new vaccines are being created more rapidly than ever before.
Vaccination 94
94 
Pfizer cut vaccine production targets because of raw material shortage – reports
pharmaphorum
DECEMBER 4, 2020
Pfizer slashed its production targets for its COVID-19 vaccine because of a lack of raw materials for its supply chain, according to press reports. The big pharma has said in recent weeks that it expects to produce 50 million doses of the vaccine it developed with the German BioNTech, down from an earlier target of 100 million doses.
Vaccination 121
121 
Pfizer Shares Positive Phase III Data for Maternal RSV Vaccine Candidate
XTalks
NOVEMBER 4, 2022
Pfizer announced positive top-line data from a Phase III trial evaluating its respiratory syncytial virus (RSV) prefusion vaccine candidate, RSVpreF (or PF-06928316) for pregnant individuals to help protect their infants from RSV disease after birth. Related: Pfizer to Acquire RSV Antiviral Developer ReViral in $525 Million Deal.
Vaccination 97
97 
Booster data backs Pfizer, Valneva Lyme disease vaccine
pharmaphorum
SEPTEMBER 28, 2021
Prospects for Valneva’s COVID-19 vaccine are up in the air, but another candidate partnered with Pfizer looks increasingly like it could fill the void of an effective shot for Lyme disease. billion contract to supply up to 100 million doses of its COVID-19 vaccine VLA2001.
Vaccination 105
105 
SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support its novel vaccine platform through accelerated clinical development
BioTech 365
FEBRUARY 10, 2021
Giebel as Chairman to support its novel vaccine platform through accelerated clinical development SpyBiotech raises $32.5M SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. in Series A funding and appoints Lutz B. Giebel as Chairman to support … Continue reading →
HIV Vaccine Trial of Vir Biotech’s New Candidate VIR-1388 Begins
XTalks
SEPTEMBER 21, 2023
announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. Since 2004, the NIAID has been championing the discovery and development of the cytomegalovirus (CMV) vector used to deliver the HIV vaccine material to the immune system without causing disease.
Vaccination 59
59 
Scepticism as Russia claims coronavirus vaccine breakthrough with Sputnik V
pharmaphorum
AUGUST 11, 2020
Russia has become the first country in the world to approve a coronavirus vaccine, amid scepticism from international experts who have been unable to review or verify clinical data from the jab called ‘Sputnik V’ According to press reports the vaccine has been tested on one of President Vladimir Putin’s daughters.
Vaccination 98
98 
Pfizer/BioNTech Begin Studies for Third Booster Dose and Development of COVID-19 Vaccine Variants
XTalks
MARCH 1, 2021
(NYSE: PFE ) and BioNTech SE (Nasdaq: BNTX ) have announced that they are beginning a trial to evaluate the safety and efficacy of a third booster dose for their COVID-19 vaccine (BNT162b2), as well as new vaccine variants. Related: Could Pfizer and BioNTech’s COVID-19 Vaccine be Stored at Standard Freezer Temperatures?
Vaccination 111
111 
EU orders 300 million doses of BioNTech/Pfizer’s COVID-19 vaccine
pharmaphorum
NOVEMBER 12, 2020
The European Union has ordered 300 million doses of BioNTech/Pfizer’s COVID-19 vaccine following this week’s landmark announcement that it was effective in more than 90% of patients. Vaccine doses for Europe will be produced in BioNTech’s German manufacturing sites, as well as in Pfizer’s manufacturing site in Belgium.
Vaccination 105
105 
The Future of Vaccine Development
VirTrial
OCTOBER 25, 2023
Vaccine studies can be large, multinational endeavors with sensitive timeframes, extended participation follow-up periods, multiphase designs, and critical data management needs. In recent years, Signant has been a part of more than 95 vaccine studies involving 140,000+ patients in more than 30 countries.
Vaccination 52
52 
Let's personalize your content